Cover Image
市場調查報告書

轉染試劑、設備的全球市場分析、預測 (∼2020年):各手法 (生物化學性手法、物理性手法、病毒性手法)、用途

Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021

出版商 MarketsandMarkets 商品編碼 334121
出版日期 內容資訊 英文 212 Pages
訂單完成後即時交付
價格
Back to Top
轉染試劑、設備的全球市場分析、預測 (∼2020年):各手法 (生物化學性手法、物理性手法、病毒性手法)、用途 Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021
出版日期: 2017年01月13日 內容資訊: 英文 212 Pages
簡介

為了滿足來自研究人員和生物科技、生物醫藥企業的必要條件,轉染試劑、設備的市場上過去數年來實現了許多的技術進步。這些進步導致高效率性的轉染設備開發,實現各種細胞的效率性且高品質的轉染。

本報告提供全球轉染試劑、設備的市場相關調查、試劑、設備種類與概要、對市場成長的各種影響因素及市場機會分析、產品、手法的市場分析及市場成長預測、各地區的趨勢、競爭環境與市場佔有率,以及主要企業的簡介等彙整。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 全球轉染技術市場
  • 各用途、地區市場
  • 各產品市場

第5章 市場概要

  • 簡介
  • 市場區隔
  • 市場動態
    • 成長推進因素
    • 阻礙成長要素
    • 市場機會
    • 課題

第6章 轉染技術市場:各產品

  • 簡介
  • 試劑
  • 設備、器具

第7章 轉染技術市場:各手法

  • 簡介
  • 生物化學的手法
    • 磷酸鈣
      • 優點
      • 缺點
    • 脂轉染
      • 優點
      • 缺點
    • DEAE-聚葡萄糖
      • 優點
      • 缺點
    • 樹狀聚合物
      • 優點
      • 缺點
  • 物理性手法
    • 簡介
    • 電穿孔
      • 優點
      • 缺點
    • 細胞核轉染
      • 優點
      • 缺點
    • 其他
      • Sonoporation
        • 優點
        • 缺點
      • 遺傳基因槍
        • 優點
        • 缺點
      • Magnetofection
        • 優點
        • 缺點
      • Optoinjection
        • 優點
        • 缺點
    • 病毒的手法
      • 簡介
      • 優點
      • 規定

第8章 轉染技術市場:各用途

  • 簡介
  • 生物醫學的研究
    • 基因表現的研究
    • 癌症研究
    • 基因轉殖模式
  • 蛋白質生成
  • 藥物輸送

第9章 全球轉染技術市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 太平洋各國
    • 其他
  • 其他
    • 南美
    • 中東、非洲

第10章 競爭環境

  • 概要
  • 市場佔有率分析
  • 競爭情形、趨勢
  • 協定、合作、策略性聯盟
  • 新產品的投入
  • 擴張
  • 收購
  • 其他

第11章 企業簡介

  • THERMO FISHER SCIENTIFIC, INC. (LIFE TECHNOLOGIES)
  • PROMEGA CORPORATION
  • QIAGEN N.V.
  • POLYPLUS TRANSFECTION SA
  • ROCHE
  • BIO-RAD LABORATORIES INC.
  • LONZA GROUP
  • SIGMA- ALDRICH CORPORATION
  • MIRUS BIO LLC.
  • MAXCYTE, INC.
    • 產業概要
    • 財務資訊
    • 產品與服務
    • 策略
    • 發展趨勢等

第12章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 3562

The global transfection reagents and equipment market is expected to reach USD 1.02 billion by 2021 from USD 715.4 million in 2016, at a CAGR of 7.5% during the forecast period 2016 to 2021.

Over the years, the transfection reagents and equipment market has witnessed various technological advancements in equipment as well as reagents to address the requirements of researchers and biotechnology & biopharmaceutical companies. These advancements have led to the development of transfection instruments that are of higher efficiency. It has also resulted in efficient quantitative and qualitative transfection in a wide range of cells, including the hard-to-transfect cells.

In 2016, the reagents segment is expected to account for the largest share of the market, by product. The biochemical method segment is expected to account for the largest share of the market, by method. The academic & research institutes segment is expected to account for the largest share of the market, by end user. The biomedical research segment is expected to account for the largest share of the market, by application.

In 2016, North America is expected to account for the largest share of the global transfection reagents and equipment market, followed by Europe, Asia-Pacific, and RoW. The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, with emphasis on India, China, and Japan. Growth in these countries can be attributed to the increase in research activities conducted in these regions, rapid expansion of the biotechnology and pharmaceutical industry, government as well as private sector support, increase in cancer incidence, and favorable regulatory framework.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopted various strategies such as agreements, collaborations and partnerships, new product launches, expansions, and acquisitions to increase their presence and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, sales and marketing directors, other innovation and technology directors, and executives from various key organizations operating in the transfection reagents and equipment market

  • By Company Type: Tier 1: 56%, Tier 2: 34%, and Tier 3: 10%
  • By Designation: Director Level: 28%, C-level: 19%, and Others: 53%
  • By Region: North America: 27%, Europe: 27%, APAC: 30%, and RoW: 16%

The prominent players in the global transfection reagents and equipment market include Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). These companies held a dominant position in the market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players in the market include Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).

Research Coverage

The report provides a picture of the transfection reagents and equipment market across different industry verticals and regions. It aims at estimating the market size and future growth potential of this market across different segments such as by product, method, end user, application, and regions. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, product pipeline, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn help firms, to garner a greater market share. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the transfection reagents and equipment market. The report analyzes the transfection reagents and equipment market, by product, method, end user, application, and region
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the transfection reagents and equipment market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various transfection methods across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the transfection technologies market
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the transfection reagents and equipment market

TABLE OF CONTENTS

1 INTRODUCTION 19

  • 1.1 OBJECTIVES OF THE STUDY 19
  • 1.2 MARKET DEFINITION 19
  • 1.3 MARKET SCOPE 20
    • 1.3.1 MARKETS COVERED 20
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 20
  • 1.4 CURRENCY 21
  • 1.5 LIMITATIONS 21
  • 1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22

  • 2.1 RESEARCH METHODOLOGY STEPS 22
  • 2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
    • 2.2.1 SECONDARY RESEARCH 23
      • 2.2.1.1 Key data from secondary sources 23
    • 2.2.2 PRIMARY RESEARCH 25
      • 2.2.2.1 Key data from primary sources 26
      • 2.2.2.2 Key insights from primary sources 26
      • 2.2.2.3 Key industry insights 27
  • 2.3 MARKET SIZE ESTIMATION METHODOLOGY 27
    • 2.3.1 MARKET FORECAST METHODOLOGY 29
  • 2.4 MARKET DATA VALIDATION AND TRIANGULATION 30
  • 2.5 ASSUMPTIONS 31

3 EXECUTIVE SUMMARY 32

  • 3.1 INTRODUCTION 32
  • 3.2 CONCLUSION 36

4 PREMIUM INSIGHTS 37

  • 4.1 GLOBAL TRANSFECTION TECHNOLOGIES MARKET 37
  • 4.2 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION & REGION 38
  • 4.3 GEOGRAPHIC SNAPSHOT: TRANSFECTION TECHNOLOGIES MARKET 39
  • 4.4 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT (2016 VS. 2021) 40
  • 4.5 TRANSFECTION TECHNOLOGIES MARKET, BY END USER,

2016 VS. 2021 (USD MILLION) 40

5 MARKET OVERVIEW 41

  • 5.1 INTRODUCTION 42
  • 5.2 MARKET DYNAMICS 42
    • 5.2.1 DRIVERS 43
      • 5.2.1.1 Technological advancements in transfection technology 43
        • 5.2.1.1.1 CRISPR-Cas9 43
        • 5.2.1.1.2 CAR-T 43
        • 5.2.1.1.3 Three Dimension (3D) transfection technology 44
      • 5.2.1.2 Global alliances among leading research institutes to trigger drug discovery 44
      • 5.2.1.3 Increase in R&D spending and research activities by pharmaceutical and biotech companies 45
      • 5.2.1.4 Growing research activities in cell science 46
      • 5.2.1.5 Increase in demand for synthetic genes 47
      • 5.2.1.6 Rising incidence of cancer worldwide 47
    • 5.2.2 RESTRAINTS 47
      • 5.2.2.1 Selective effectiveness of transfection reagents 47
      • 5.2.2.2 Home brew reagents restrict sale of commercial kits 47
      • 5.2.2.3 High cost of transfection reagents 48
    • 5.2.3 OPPORTUNITIES 48
      • 5.2.3.1 Large-scale transfections 48
      • 5.2.3.2 High-growth opportunities in asian market 48
        • 5.2.3.2.1 India 49
        • 5.2.3.2.2 China 49
    • 5.2.4 CHALLENGES 50
      • 5.2.4.1 Transfection in hard-to-transfect cells 50
      • 5.2.4.2 Cytotoxicity in transfection - a major concern 50

6 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT 51

  • 6.1 INTRODUCTION 52
  • 6.2 REAGENTS 53
  • 6.3 EQUIPMENT 55

7 TRANSFECTION TECHNOLOGIES MARKET, BY METHOD 56

  • 7.1 INTRODUCTION 57
  • 7.2 BIOCHEMICAL METHODS 58
    • 7.2.1 LIPOFECTION 60
      • 7.2.1.1 Advantages 60
      • 7.2.1.2 Disadvantages 60
    • 7.2.2 CALCIUM PHOSPHATE 61
      • 7.2.2.1 Advantages 61
      • 7.2.2.2 Disadvantages 62
    • 7.2.3 DEAE-DEXTRAN 62
      • 7.2.3.1 Advantages 62
      • 7.2.3.2 Disadvantages 63
    • 7.2.4 DENDRIMERS 63
      • 7.2.4.1 Advantages 63
      • 7.2.4.2 Disadvantages 64
  • 7.3 PHYSICAL 64
    • 7.3.1 ELECTROPORATION 66
      • 7.3.1.1 Advantages 66
      • 7.3.1.2 Disadvantages 66
    • 7.3.2 NUCLEOFECTION 67
      • 7.3.2.1 Advantages 67
      • 7.3.2.2 Disadvantages 67
    • 7.3.3 OTHER METHODS 68
      • 7.3.3.1 Sonoporation 68
      • 7.3.3.2 Genegun 68
        • 7.3.3.2.1 Advantages 68
        • 7.3.3.2.2 Disadvantages 68
      • 7.3.3.3 Magnetofection 69
        • 7.3.3.3.1 Advantages 69
        • 7.3.3.3.2 Disadvantages 69
      • 7.3.3.4 Optoinjection 69
        • 7.3.3.4.1 Advantages 69
        • 7.3.3.4.2 Disadvantages 69
  • 7.4 VIRAL METHODS 70
    • 7.4.1 ADENOVIRUSES 71
    • 7.4.2 RETROVIRUSES 71
    • 7.4.3 ADENOASSOCIATED VIRUSES (AAV) 71

8 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION 73

  • 8.1 INTRODUCTION 74
  • 8.2 BIOMEDICAL RESEARCH 75
    • 8.2.1 GENE EXPRESSION STUDIES 77
    • 8.2.2 CANCER RESEARCH 78
    • 8.2.3 TRANSGENIC MODELS 79
  • 8.3 PROTEIN PRODUCTION 80
  • 8.4 THERAPEUTIC DELIVERY 81

9 TRANSFECTION TECHNOLOGIES MARKET, BY END USER 83

  • 9.1 INTRODUCTION 84
  • 9.2 ACADEMICS & RESEARCH INSTITUTES 85
  • 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 86

10 TRANSFECTION TECHNOLOGIES MARKET, BY REGION 88

  • 10.1 INTRODUCTION 89
  • 10.2 NORTH AMERICA 90
    • 10.2.1 U.S. 96
      • 10.2.1.1 Increase in bio-based drug research 96
      • 10.2.1.2 Growing demand for protein-based therapeutics triggers the growth of U.S. market 96
      • 10.2.1.3 Increasing funding for biotechnology and for development of protein-based biologics 97
      • 10.2.1.4 Conferences/meetings/symposiums/workshops 97
    • 10.2.2 CANADA 102
      • 10.2.2.1 Government support for development of protein drugs is expected to drive the market for transfection technologies 102
      • 10.2.2.2 Increasing investments by the canadian government on regenerative medicine to drive market growth 102
      • 10.2.2.3 Increasing funding for genome engineering in Canada likely to boost transfection technologies market 103
  • 10.3 EUROPE 107
    • 10.3.1 GERMANY 113
      • 10.3.1.1 Growing biotech industry and research funding in germany 113
      • 10.3.1.2 Collaboration among bio-pharmaceutical and biotechnology companies for the development of new vaccines is likely to drive the market growth 113
      • 10.3.1.3 Conferences and meetings/workshops in Germany 114
      • 10.3.1.4 Availability of funding for life science research in Germany 114
    • 10.3.2 U.K. 118
      • 10.3.2.1 10,000 genome project initiative in U.K. 118
      • 10.3.2.2 Initiative to increase R&D investments in U.K. 119
    • 10.3.3 REST OF EUROPE 123
      • 10.3.3.1 Growing biotechnology and pharma industry in Italy 123
      • 10.3.3.2 Focus on research in Spain 123
      • 10.3.3.3 Investments and funding for life sciences to drive the transfection technologies market 123
      • 10.3.3.4 Growing research investments in Sweden & Denmark 124
  • 10.4 ASIA-PACIFIC 129
    • 10.4.1 JAPAN 135
      • 10.4.1.1 Rise in biomedical research in Japan 135
    • 10.4.2 CHINA 139
      • 10.4.2.1 Chinese government initiatives for life sciences R&D likely to boost the market 139
      • 10.4.2.2 Industry initiative to boost transfection technology market in China 140
    • 10.4.3 INDIA 144
      • 10.4.3.1 Booming pharmaceutical and biotechnology industries 144
      • 10.4.3.2 Development of bio-clusters in India 144
    • 10.4.4 REST OF ASIA-PACIFIC 149
      • 10.4.4.1 Federal collaborations in Australia 149
      • 10.4.4.2 Funding for research on proteomics and genomics in Australia 149
      • 10.4.4.3 Rising pharmaceutical and biotechnology R&D activities in South Korea 150
      • 10.4.4.4 Government support for strong academic and commercial R&D activities in Taiwan 150
      • 10.4.4.5 Genome Asia 100k initative 151
  • 10.5 REST OF THE WORD (ROW) 155
    • 10.5.1 LATIN AMERICA 155
      • 10.5.1.1 Increasing investment in Brazil and Mexico 155
      • 10.5.1.2 Brazil: investment in research and innovation centers and conferences & workshops 156
    • 10.5.2 MIDDLE EAST & AFRICA 156
      • 10.5.2.1 Increasing focus of major pharmaceutical, biopharmaceutical, and biotechnology firms in Saudi Arabia and the United Arab Emirates (UAE) and African regions 156
      • 10.5.2.2 Genetic testing and genomic analysis in the Middle East 157

11 COMPETITIVE LANDSCAPE 161

  • 11.1 OVERVIEW 161
  • 11.2 MARKET SHARE ANALYSIS 162
    • 11.2.1 INTRODUCTION 162
    • 11.2.2 THERMO FISHER SCIENTIFIC INC. 163
    • 11.2.3 PROMEGA CORPORATION 164
    • 11.2.4 F. HOFFMANN-LA ROCHE LTD 164
    • 11.2.5 QIAGEN N.V. 164
  • 11.3 COMPETITIVE SITUATION AND TRENDS 165
  • 11.4 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS 166
  • 11.5 NEW PRODUCT LAUNCHES 168
  • 11.6 EXPANSIONS 169
  • 11.7 ACQUISITIONS 170
  • 11.8 OTHER STRATEGIES 171

12 COMPANY PROFILES 172

(Overview, Products and Services, Financials, Strategy & Development)*

  • 12.1 THERMO FISHER SCIENTIFIC INC. (LIFE TECHNOLOGIES) 172
  • 12.2 PROMEGA CORPORATION 175
  • 12.3 QIAGEN N.V. 177
  • 12.4 F. HOFFMANN-LA ROCHE LTD 180
  • 12.5 BIO-RAD LABORATORIES, INC. 182
  • 12.6 MAXCYTE, INC. 184
  • 12.7 LONZA GROUP LTD. 186
  • 12.8 MERCK KGAA 189
  • 12.9 POLYPLUS-TRANSFECTION SA (SUBSIDARY OF ARCHIMED) 193
  • 12.10 MIRUS BIO LLC. 195

Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.

13 APPENDIX 198

  • 13.1 DISCUSSION GUIDE 198
  • 13.2 OTHER DEVELOPMENTS 203
    • 13.2.1 MAXCYTE INC. 203
    • 13.2.2 LONZA GROUP LTD. 203
    • 13.2.3 QIAGEN N.V. 203
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 204
  • 13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 206
  • 13.5 AVAILABLE CUSTOMIZATIONS 207
  • 13.6 RELATED REPORTS 208
  • 13.7 AUTHOR DETAILS 209

LIST OF TABLES

  • TABLE 1 INDICATIVE LIST OF CELL-BASED RESEARCH STUDIES 46
  • TABLE 2 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 53
  • TABLE 3 TRANSFECTION REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 54
  • TABLE 4 TRANSFECTION INSTRUMENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 55
  • TABLE 5 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 58
  • TABLE 6 BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 59
  • TABLE 7 BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 59
  • TABLE 8 LIPOFECTION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 61
  • TABLE 9 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR CALCIUM PHOSPHATE METHOD, BY REGION, 2014-2021 (USD MILLION) 62
  • TABLE 10 DEAE-DEXTRAN TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 63
  • TABLE 11 DENDRIMER TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 64
  • TABLE 12 PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 65
  • TABLE 13 PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 65
  • TABLE 14 ELECTROPORATION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 66
  • TABLE 15 NUCLEOFECTION TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 67
  • TABLE 16 OTHER PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 70
  • TABLE 17 VIRAL SYSTEMS 71
  • TABLE 18 VIRAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 72
  • TABLE 19 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 75
  • TABLE 20 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 76
  • TABLE 21 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY REGION, 2014-2021 (USD MILLION) 76
  • TABLE 22 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR GENE EXPRESSION STUDIES, BY REGION, 2014-2021 (USD MILLION) 77
  • TABLE 23 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR CANCER RESEARCH, BY REGION, 2014-2021 (USD MILLION) 78
  • TABLE 24 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR TRANSGENIC MODELS, BY REGION, 2014-2021 (USD MILLION) 79
  • TABLE 25 INDICATIVE LIST OF FEW RECOMBINANT PROTEINS, VACCINES FROM DIFFERENT CELL TYPES 80
  • TABLE 26 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PROTEIN PRODUCTION, BY REGION, 2014-2021 (USD MILLION) 80
  • TABLE 27 INDICATIVE LIST OF DRUG DELIVERY SYSTEMS FOR VARIOUS DISEASE CONDITIONS 81
  • TABLE 28 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR THERAPEUTIC DELIVERY, BY REGION, 2014-2021 (USD MILLION) 82
  • TABLE 29 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 85
  • TABLE 30 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR ACADEMICS & RESEARCH INSTITUTES, BY REGION, 2014-2021 (USD MILLION) 86
  • TABLE 31 TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD MILLION) 87
  • TABLE 32 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 90
  • TABLE 33 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION) 92
  • TABLE 34 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 92
  • TABLE 35 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 93
  • TABLE 36 NORTH AMERICA: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 93
  • TABLE 37 NORTH AMERICA: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 94
  • TABLE 38 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 94
  • TABLE 39 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 95
  • TABLE 40 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 95
  • TABLE 41 LIST OF MONOCLONAL ANTIBODIES APPROVED BY FDA IN 2015 97
  • TABLE 42 INDICATIVE LIST OF UPCOMING EVENTS IN THE U.S. 98
  • TABLE 43 U.S.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 98
  • TABLE 44 U.S.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 99
  • TABLE 45 U.S.: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 99
  • TABLE 46 U.S.: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 100
  • TABLE 47 U.S.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 100
  • TABLE 48 U.S.: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 101
  • TABLE 49 U.S.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 101
  • TABLE 50 CANADA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 104
  • TABLE 51 CANADA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 104
  • TABLE 52 CANADA: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 105
  • TABLE 53 CANADA: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 105
  • TABLE 54 CANADA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 106
  • TABLE 55 CANADA: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 106
  • TABLE 56 CANADA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 107
  • TABLE 57 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION) 109
  • TABLE 58 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 109
  • TABLE 59 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 110
  • TABLE 60 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOCHEMICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 110
  • TABLE 61 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PHYSICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 111
  • TABLE 62 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 111
  • TABLE 63 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 112
  • TABLE 64 EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 112
  • TABLE 65 INDICATIVE LIST OF UPCOMING EVENTS IN GERMANY 114
  • TABLE 66 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 115
  • TABLE 67 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 115
  • TABLE 68 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOCHEMICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 116
  • TABLE 69 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PHYSICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 116
  • TABLE 70 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 117
  • TABLE 71 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 117
  • TABLE 72 GERMANY: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 118
  • TABLE 73 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 119
  • TABLE 74 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 120
  • TABLE 75 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE BIOCHEMICAL METHOD, BY TYPE 2014-2021 (USD MILLION) 120
  • TABLE 76 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE PHYSICAL METHOD, BY TYPE 2014-2021 (USD MILLION) 121
  • TABLE 77 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 121
  • TABLE 78 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 122
  • TABLE 79 U.K.: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 122
  • TABLE 80 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 125
  • TABLE 81 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 125
  • TABLE 82 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOCHEMICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 126
  • TABLE 83 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PHYSICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 126
  • TABLE 84 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 127
  • TABLE 85 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 127
  • TABLE 86 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 128
  • TABLE 87 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION) 131
  • TABLE 88 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 131
  • TABLE 89 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 132
  • TABLE 90 ASIA-PACIFIC: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 132
  • TABLE 91 ASIA-PACIFIC: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 133
  • TABLE 92 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 133
  • TABLE 93 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 134
  • TABLE 94 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 134
  • TABLE 95 JAPAN: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 136
  • TABLE 96 JAPAN: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 136
  • TABLE 97 JAPAN: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 137
  • TABLE 98 JAPAN: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 137
  • TABLE 99 JAPAN: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 138
  • TABLE 100 JAPAN: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 138
  • TABLE 101 JAPAN: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 139
  • TABLE 102 CHINA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 140
  • TABLE 103 CHINA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 141
  • TABLE 104 CHINA: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 141
  • TABLE 105 CHINA: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 142
  • TABLE 106 CHINA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 142
  • TABLE 107 CHINA: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 143
  • TABLE 108 CHINA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 143
  • TABLE 109 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 145
  • TABLE 110 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 146
  • TABLE 111 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOCHEMICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 146
  • TABLE 112 INDIA: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 147
  • TABLE 113 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 147
  • TABLE 114 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 148
  • TABLE 115 INDIA: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 148
  • TABLE 116 REST OF ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 151
  • TABLE 117 REST OF ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 151
  • TABLE 118 REST OF ASIA-PACIFIC: BIOCHEMICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 152
  • TABLE 119 REST OF ASIA-PACIFIC: PHYSICAL TRANSFECTION TECHNOLOGIES MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 152
  • TABLE 120 REST OF ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 153
  • TABLE 121 REST OF ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 153
  • TABLE 122 REST OF ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 154
  • TABLE 123 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 157
  • TABLE 124 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 158
  • TABLE 125 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOCHEMICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 158
  • TABLE 126 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR PHYSICAL METHOD, BY TYPE, 2014-2021 (USD MILLION) 159
  • TABLE 127 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION) 159
  • TABLE 128 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE FOR BIOMEDICAL RESEARCH, BY TYPE, 2014-2021 (USD MILLION) 160
  • TABLE 129 ROW: TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2014-2021 (USD MILLION) 160
  • TABLE 130 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 2013-2016 167
  • TABLE 131 NEW PRODUCT LAUNCHES, 2013-2016 168
  • TABLE 132 EXPANSIONS, 2013-2016 169
  • TABLE 133 ACQUISITIONS, 2013-2016 170
  • TABLE 134 OTHER STRATEGIES, 2013-2016 171

LIST OF FIGURES

  • FIGURE 1 RESEARCH METHODOLOGY: GLOBAL TRANSFECTION TECHNOLOGIES MARKET 22
  • FIGURE 2 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 25
  • FIGURE 3 SAMPLING FRAME: PRIMARY RESEARCH 25
  • FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 28
  • FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 28
  • FIGURE 6 RESEARCH DESIGN: GLOBAL TRANSFECTION TECHNOLOGIES MARKET 29
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY 30
  • FIGURE 8 TRANSFECTION TECHNOLOGIES MARKET, BY METHOD (2016) 32
  • FIGURE 9 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT (2016-2021) 33
  • FIGURE 10 TRANSFECTION TECHNOLOGIES MARKET, BY END USER, 2016 VS. 2021 34
  • FIGURE 11 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION, 2016 VS. 2021 (USD MILLION) 35
  • FIGURE 12 ASIA-PACIFIC IS PROJECTED TO WITNESS THE HIGHEST GROWTH IN THE TRANSFECTION TECHNOLOGIES MARKET DURING THE FORECAST PERIOD 36
  • FIGURE 13 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 37
  • FIGURE 14 BIOMEDICAL RESEARCH SEGMENT TO DOMINATE THE TRANSFECTION TECHNOLOGIES MARKET IN 2016 38
  • FIGURE 15 ASIA-PACIFIC IS PROJECTED TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 39
  • FIGURE 16 REAGENTS SEGMENT IS PROJECTED TO ACCOUNT FOR THE LARGEST SHARE THROUGH 2021 40
  • FIGURE 17 ACADEMIC & RESEARCH INSTITUTES SEGMENT IS EXPECTED TO DOMINATE THE MARKET THROUGH 2021 40
  • FIGURE 18 MARKET DYNAMICS 42
  • FIGURE 19 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY PRODUCT, 2016-2021 (USD MILLION) 52
  • FIGURE 20 TRANSFECTION TECHNOLOGIES MARKET, BY METHOD, 2016 VS. 2021 (USD MILLION) 57
  • FIGURE 21 TRANSFECTION TECHNOLOGIES MARKET: BY APPLICATION 74
  • FIGURE 22 TRANSFECTION TECHNOLOGIES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION) 84
  • FIGURE 23 TRANSFECTION TECHNOLOGIES MARKET: BY REGION, 2016-2021 89
  • FIGURE 24 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SNAPSHOT 91
  • FIGURE 25 EUROPE : TRANSFECTION TECHNOLOGIES MARKET SNAPSHOT 108
  • FIGURE 26 ASIA-PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SNAPSHOT 130
  • FIGURE 27 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, ARE THE MAJOR STRATEGIES ADOPTED BY THE KEY PLAYERS, 2013-2016 161
  • FIGURE 28 GLOBAL TRANSFECTION TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2015 162
  • FIGURE 29 AGREEMENTS,COLLABORATIONS, AND PARTNERSHIPS: KEY STRATEGY ADOPTED BY PLAYERS (2013-2016) 165
  • FIGURE 30 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS, BY COMPANY (2013-2016) 166
  • FIGURE 31 NEW PRODUCT LAUNCHES, BY COMPANY (2013-2016) 168
  • FIGURE 32 EXPANSIONS, BY COMPANY (2013-2016) 169
  • FIGURE 33 ACQUISITION, BY COMPANY (2013-2016) 170
  • FIGURE 34 OTHER STRATEGIES, BY COMPANY (2013-2016) 171
  • FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 172
  • FIGURE 36 PROMEGA CORPORATION: COMPANY SNAPSHOT 175
  • FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT 177
  • FIGURE 38 ROCHE: COMPANY SNAPSHOT 180
  • FIGURE 39 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 182
  • FIGURE 40 MAXCYTE INC.: COMPANY SNAPSHOT 184
  • FIGURE 41 LONZA GROUP: COMPANY SNAPSHOT 186
  • FIGURE 42 MERCK KGAA : COMPANY SNAPSHOT 189
  • FIGURE 43 SIGMA ALDRICH CORPORATION : COMPANY SNAPSHOT 190
Back to Top